BBK was engaged to support the enrollment of a study in South Korea evaluating a PD-1 immune checkpoint inhibitor in patients with esophageal cancer refractory or intolerant to common treatment.
Because of concerns about sharing patient information, the strategy shifted from generating patient referrals to focusing on physician awareness in an effort to inform relevant physicians about the study. In all key benchmarks, BBK met or exceeded the client’s expectations, and resulted in identifying 27 physicians interested in referring one or more patients to the study.
A last-minute shift in strategy from the sponsor required significant operational adjustments, including changes to outreach tactics and the physician-facing study website.
During the deployment of outreach, the sponsor requested that timelines be accelerated by two weeks—reducing the amount of time to generate new referrals.
To generate sufficient referrals, efforts needed to engage physicians on a local level and foster conversation among colleagues.
Leveraging BBK’s network of physicians who specialize in esophageal cancer in Korea, BBK identified, assessed and reached out to 105 physicians with direct-to-physician emails.
BBK conducted phone calls with physicians and site staff to raise awareness for the study and to encourage referrals.
In just six weeks, the physician website had 47 unique visitors. 27 physicians expressed interest in referring 1 or more of their patients to the study, exceeding expectations.
Download the PDF version of this case study today:
Case Studies
May 30, 2023
Case Studies
May 30, 2023
Case Studies
May 30, 2023
BBK Worldwide, LLC
117 Kendrick St., Suite 600
Needham, MA 02494 United States
Terms & Conditions Privacy Policy
© 2023 BBK Worldwide. BBK Worldwide is a Publicis Health company.
Terms & Conditions Privacy Policy
© 2023 BBK Worldwide. BBK Worldwide is a Publicis Health company.